India : Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility

Sovereign Project | 55082-001

The project will benefit significantly from an abbreviated consideration period by the Asian Development Bank (ADB) Board of Directors since it supports the Government of India's rapid vaccination rollout to contain the ongoing pandemic and the severity of a possible third wave as well as the loss of lives. The government has already placed orders for APVAX-eligible vaccines and incurred substantial costs from the accelerated pace of vaccination since August 2021. Timely ADB support would add value by helping meet urgent financing needs for delivering APVAX eligible vaccines for priority population, and allow government resources to procure the planned non-APVAX eligible vaccines. Vaccine financing would also safeguard essential expenditure on emergency response needs, strengthen the resilience of health systems, and contribute to the country's commitment to an earlier resumption of vaccine export.

Project Details

  • Project Officer
    Yadav, Madhusudan Patirajprasad
    South Asia Department
    Request for information
  • Country/Economy
    India
  • Sector
    • Health
Project Name Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility
Project Number 55082-001
Country / Economy India
Project Status Active
Project Type / Modality of Assistance Loan
Source of Funding / Amount
Loan 4151-IND: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility
Ordinary capital resources US$ 1,000.00 million
Loan 4147-IND: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility
Ordinary capital resources US$ 500.00 million
Loan 8408-IND: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility
Asian Infrastructure Investment Bank US$ 500.00 million
Operational Priorities OP1: Addressing remaining poverty and reducing inequalities
OP2: Accelerating progress in gender equality
OP3: Tackling climate change, building climate and disaster resilience, and enhancing environmental sustainability
OP7: Fostering regional cooperation and integration
Sector / Subsector

Health / Disease control of communicable disease

Gender Effective gender mainstreaming
Description

The project will benefit significantly from an abbreviated consideration period by the Asian Development Bank (ADB) Board of Directors since it supports the Government of India's rapid vaccination rollout to contain the ongoing pandemic and the severity of a possible third wave as well as the loss of lives. The government has already placed orders for APVAX-eligible vaccines and incurred substantial costs from the accelerated pace of vaccination since August 2021. Timely ADB support would add value by helping meet urgent financing needs for delivering APVAX eligible vaccines for priority population, and allow government resources to procure the planned non-APVAX eligible vaccines. Vaccine financing would also safeguard essential expenditure on emergency response needs, strengthen the resilience of health systems, and contribute to the country's commitment to an earlier resumption of vaccine export.

The project will provide the government with timely financing to procure safe and effective coronavirus disease (COVID-19) vaccines based on an agreed list of eligible expenditures under the rapid response component (RRC) of the Asia Pacific Vaccine Access Facility (APVAX). Ongoing technical assistance (TA) will complement the project by strengthening the vaccine delivery system.

Project Rationale and Linkage to Country/Regional Strategy

Since the first case of COVID-19 was confirmed in India on 30 January 2020, another 33,236,920 cases were confirmed and 442,655 people have died from the virus as of 12 September 2021. The pandemic resulted in very high costs to the country's overall health, well-being, and economy. India faced a devastating second wave starting March 2021, which peaked with a record high of 414,188 new COVID-19 cases on 7 May 2021. This was about 32% higher than the world's previous peak reported by the United States in 2020. The second wave in India overwhelmed hospitals and exhausted health workers, who were increasingly becoming infected. Despite the containment measures with localized lockdowns and social distancing, increased testing capacity (more than 2.2 million samples per day) to detect and isolate cases, and a national vaccination drive, the possibility of a third wave looms large because of highly contagious variants.

Equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic and has proven to be lifesaving. Recognizing this need, the government started rolling out inoculations on 16 January 2021. More than 738.2 million vaccine doses had been administered in more than 7.5 million sessions by 12 September 2021. India aims to inoculate 944.7 million people (68.9% of its total population). Given the devastating second wave and the possible threat of a third wave, the government allocated significant financing to health system strengthening efforts, which further strained its resource envelope. The government requires immediate financial support to procure eligible vaccines to inoculate its target population and limit the adverse impacts of the pandemic.

Impact

Accelerated health, social, and economic recovery from COVID-19 in India (NDVP for COVID-19 Vaccine)

Project Outcome
Description of Outcome

Eligible populations safely vaccinated against COVID-19 in project states

Progress Toward Outcome As on 30th June 2022, a total of 1890.6 million doses have been administered across the project States. This includes 971.6 million first dose, 876.7 million second dose and 42.2 million precaution dose among the eligible population.
Implementation Progress
Description of Project Outputs

Safe and effective COVID-19 vaccines supplied for eligible population in project states

Status of Implementation Progress (Outputs, Activities, and Issues) As on 30th June 2022, re-imbursement for 389.1 million doses (38, 91, 79,654.5 doses) has been done under APVAX facility which were delivered to the 19 project States.
Geographical Location Nation-wide, Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh, West Bengal
Safeguard Categories
Environment C
Involuntary Resettlement C
Indigenous Peoples C
Summary of Environmental and Social Aspects
Environmental Aspects
Involuntary Resettlement
Indigenous Peoples
Stakeholder Communication, Participation, and Consultation
During Project Design
During Project Implementation

Between August 2021 and May 2022, UNICEF's supported Risk Communication and Community Engagement (RCCE) interventions contributed to vaccination of close to 200,000 people, including 46,500 children (12-17 years-old), in rural areas and marginalised groups in urban slums. Total 151,000 persons, including 97,000 women received face-to-face information on challenges pertaining to the uptake of the second dose of the COVID-19 vaccine, launch of children's COVID-19 vaccination drive, and social protection schemes for the most vulnerable, through state, hamlets, village level advocacy and mobilization meetings. In addition, a cumulative total of 802 hamlet level meetings was conducted.

Awareness on Har Ghar Dastak' campaign 2.0: This was launched on 01 June, 2022 to expedite COVID-19 vaccination coverage in India. This is a door-to-door campaign with the prime focus is to vaccinate eligible population for first dose, emphasize on the need of the second dose and the importance for the precaution dose for all eligible beneficiaries including coverage for >= 60 years' age group.

Business Opportunities
Procurement Direct contracting
Responsible ADB Officer Yadav, Madhusudan Patirajprasad
Responsible ADB Department South Asia Department
Responsible ADB Division India Resident Mission
Executing Agencies
Ministry of Health and Family Welfare
Timetable
Concept Clearance 01 Jan 2023
Fact Finding 11 Aug 2021 to 21 Sep 2021
MRM 28 Sep 2021
Approval 25 Nov 2021
Last Review Mission -
Last PDS Update 02 Dec 2022

Loan 4147-IND

Milestones
Approval Signing Date Effectivity Date Closing
Original Revised Actual
25 Nov 2021 31 Dec 2021 01 Feb 2022 30 Jun 2025 - -
Financing Plan Loan Utilization
Total (Amount in US$ million) Date ADB Others Net Percentage
Project Cost 557.77 Cumulative Contract Awards
ADB 500.00 26 Apr 2023 499.34 0.00 100%
Counterpart 57.77 Cumulative Disbursements
Cofinancing 0.00 26 Apr 2023 499.33 0.00 100%
Status of Covenants
Category Sector Safeguards Social Financial Economic Others
Rating Satisfactory Satisfactory Satisfactory Satisfactory - Satisfactory

Loan 4151-IND

Milestones
Approval Signing Date Effectivity Date Closing
Original Revised Actual
25 Nov 2021 31 Dec 2021 01 Feb 2022 30 Jun 2025 - -
Financing Plan Loan Utilization
Total (Amount in US$ million) Date ADB Others Net Percentage
Project Cost 1,000.00 Cumulative Contract Awards
ADB 1,000.00 26 Apr 2023 590.93 0.00 99%
Counterpart 0.00 Cumulative Disbursements
Cofinancing 0.00 26 Apr 2023 578.60 0.00 97%
Status of Covenants
Category Sector Safeguards Social Financial Economic Others
Rating Satisfactory Satisfactory Satisfactory Satisfactory - Satisfactory

Loan 8408-IND

Milestones
Approval Signing Date Effectivity Date Closing
Original Revised Actual
20 Jan 2022 31 Dec 2021 10 Feb 2022 30 Jun 2025 - -
Financing Plan Loan Utilization
Total (Amount in US$ million) Date ADB Others Net Percentage
Project Cost 500.00 Cumulative Contract Awards
ADB 0.00 26 Apr 2023 0.00 405.80 101%
Counterpart 0.00 Cumulative Disbursements
Cofinancing 500.00 26 Apr 2023 0.00 398.23 99%

Project Data Sheets (PDS) contain summary information on the project or program. Because the PDS is a work in progress, some information may not be included in its initial version but will be added as it becomes available. Information about proposed projects is tentative and indicative.

The Access to Information Policy (AIP) recognizes that transparency and accountability are essential to development effectiveness. It establishes the disclosure requirements for documents and information ADB produces or requires to be produced.

The Accountability Mechanism provides a forum where people adversely affected by ADB-assisted projects can voice and seek solutions to their problems and report alleged noncompliance of ADB's operational policies and procedures.

In preparing any country program or strategy, financing any project, or by making any designation of, or reference to, a particular territory or geographic area in this document, the Asian Development Bank does not intend to make any judgments as to the legal or other status of any territory or area.


Safeguard Documents See also: Safeguards
Safeguard documents provided at the time of project/facility approval may also be found in the list of linked documents provided with the Report and Recommendation of the President.

None currently available.


Evaluation Documents See also: Independent Evaluation

None currently available.


Related Publications

None currently available.


The Access to Information Policy (AIP) establishes the disclosure requirements for documents and information ADB produces or requires to be produced in its operations to facilitate stakeholder participation in ADB's decision-making. For more information, refer to the Safeguard Policy Statement, Operations Manual F1, and Operations Manual L3.

Requests for information may also be directed to the InfoUnit.

Tenders

No tenders for this project were found.

Contracts Awarded

No contracts awarded for this project were found

Procurement Plan